These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20976259)

  • 21. Chronic p27
    Patki M; McFall T; Rosati R; Huang Y; Malysa A; Polin L; Fielder A; Wilson MR; Lonardo F; Back J; Li J; Matherly LH; Bepler G; Ratnam M
    Sci Rep; 2018 Oct; 8(1):16006. PubMed ID: 30375484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising molecular mechanisms responsible for gemcitabine resistance in cancer.
    Jia Y; Xie J
    Genes Dis; 2015 Dec; 2(4):299-306. PubMed ID: 30258872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.
    Patki M; Gadgeel S; Huang Y; McFall T; Shields AF; Matherly LH; Bepler G; Ratnam M
    J Thorac Oncol; 2014 Apr; 9(4):519-26. PubMed ID: 24736075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
    J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.
    Wang L; Xiang S; Williams KA; Dong H; Bai W; Nicosia SV; Khochbin S; Bepler G; Zhang X
    PLoS One; 2012; 7(9):e44265. PubMed ID: 22957056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
    Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
    Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
    Zhu CM; Lian XY; Bi YH; Hu CC; Liang YW; Li QS
    Clin Chim Acta; 2018 Oct; 485():67-73. PubMed ID: 29803896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines.
    Zhou J; Oliveira P; Li X; Chen Z; Bepler G
    J Nucleic Acids; 2010 Sep; 2010():597098. PubMed ID: 20976259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.
    Reid G; Wallant NC; Patel R; Antonic A; Saxon-Aliifaalogo F; Cao H; Webster G; Watson JD
    J RNAi Gene Silencing; 2009 Mar; 5(1):321-30. PubMed ID: 19771229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

  • 33. Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
    Wakai T; Shirai Y; Sakata J; Takamura M; Matsuda Y; Korita PV; Muneoka K; Sasaki M; Ajioka Y; Hatakeyama K
    Hepatogastroenterology; 2011; 58(110-111):1659-63. PubMed ID: 21940346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
    Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
    J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
    Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
    Bepler G; Sommers KE; Cantor A; Li X; Sharma A; Williams C; Chiappori A; Haura E; Antonia S; Tanvetyanon T; Simon G; Obasaju C; Robinson LA
    J Thorac Oncol; 2008 Oct; 3(10):1112-8. PubMed ID: 18827606
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.